• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Antihistamine Drugs Market

    ID: MRFR/Pharma/2913-HCR
    206 Pages
    Rahul Gotadki
    September 2025

    Antihistamine Drugs Market Research Report Information by Type (Sedating and Non-Sedating), By Route of Administration (Oral Route, Parenteral Route, and Rectal Route), By Indication (Allergy, Urticaria, and Dermatitis), By End User (Hospitals, Clinics, and Pharmaceutical Companies), And by Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Antihistamine Drugs Market Research Report - Forecast Till 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    Antihistamine Drugs Market Summary

    The global antihistamine drugs market is projected to grow from 0.17 USD billion in 2024 to 0.44 USD billion by 2035, indicating a robust growth trajectory.

    Key Market Trends & Highlights

    Antihistamine Drugs Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 8.93% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 0.44 USD billion, reflecting increasing consumer demand.
    • In 2024, the market is valued at 0.17 USD billion, highlighting its current size and potential for expansion.
    • Growing adoption of antihistamine drugs due to rising allergy prevalence is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.17 (USD Billion)
    2035 Market Size 0.44 (USD Billion)
    CAGR (2025-2035) 8.93%

    Major Players

    Johnson & Johnson Consumer Inc., Sanofi, Bayer AG, Pfizer, CVS pharmacy, Merck Sharp & Dohme Corp., Prestige Brands Holdings, Inc.

    Antihistamine Drugs Market Trends

    Growing awareness about therapies related to allergies is driving the market growth

    Market CAGR for antihistamine drugs is being driven by the rising awareness about therapies related to allergies. The growing incidence of allergic responses and allergies worldwide and increased public knowledge about managing various reactions to allergens are the primary drivers impacting this market. Allergies remedies are projected to become more popular due to changing lifestyles and innovative pharmacological solutions. There is a considerable demand for these medicines, and the number of people is growing. However, patent expiry, the launch of generic forms of drugs, and the treatment of adverse reactions will likely restrain market expansion throughout the projection period.

    Allergic rhinitis has grown over the previous three decades, as reported by the American College of Allergy, Asthma, and Immunology—40% of the people in the United States and Europe to inhalant allergens.

    Additionally, changes in lifestyle and the launch of innovative medication treatments for managing allergy illnesses are projected to drive market expansion throughout the forecast period. New product releases and FDA permission for over-the-counter switching of prescription-based nasal sprays are expected to provide attractive opportunities to major industry participants. Collaboration with regional and local players is expected to assist businesses in expanding their geographic reach and offering of goods.

    Because nasal antihistamines are the most efficient and popular route of administration, the COVID-19 epidemic boosted sales. However, antihistamine sales were hindered to some amount by restricted international borders, supply delivery networks, stock shortages, and lockdown limitations. According to FMI estimates, the COVID-19 industry will rebound in the following years. This is because of the rise in the need for nose sprays and the number of people who rely on this treatment. These trends will continue in the face of healthcare changes, affecting the demand forecast.

    For instance, According to WHO's White Book on Allergy 2011-2012, allergic rhinitis impacted 10%-30% of the population, whereas the average lifetime incidence of urticarial disease was above 20%. A high prevalence of allergies and a rise in incidences among youngsters are expected to increase antihistamine consumption throughout the predicted period. Therefore, it is anticipated that demand for Antihistamine Drugs will increase throughout the projection period due to the rising awareness about allergies-related therapies. Thus, driving the Antihistamine Drugs market revenue.

    The ongoing rise in allergic conditions globally appears to be driving a sustained demand for antihistamine drugs, reflecting a growing public health concern.

    U.S. Food and Drug Administration (FDA)

    Antihistamine Drugs Market Drivers

    Rising Allergy Incidence

    The increasing prevalence of allergic conditions globally drives the demand for antihistamine drugs. With a notable rise in allergies, particularly in urban areas, the Global Antihistamine Drugs Market Industry is experiencing heightened interest. For instance, the World Health Organization indicates that allergic rhinitis affects approximately 10 to 30 percent of the global population. This growing incidence is likely to propel the market, with projections estimating a market value of 0.17 USD Billion in 2024. As awareness of allergy management increases, the demand for effective antihistamines is expected to rise, further stimulating market growth.

    Market Growth Projections

    The Global Antihistamine Drugs Market Industry is poised for substantial growth, with projections indicating a market value of 0.17 USD Billion in 2024 and an anticipated increase to 0.44 USD Billion by 2035. This growth represents a compound annual growth rate of 8.93 percent from 2025 to 2035. Such projections reflect the increasing demand for antihistamines driven by rising allergy incidences, advancements in drug formulations, and growing consumer awareness. The market's expansion is likely to be supported by ongoing research and development efforts, regulatory support, and the evolving landscape of consumer preferences.

    Growing Awareness of Allergies

    There is a growing awareness of allergies and their management among the global population, which is positively impacting the Global Antihistamine Drugs Market Industry. Educational campaigns and increased access to information have led to better recognition of allergy symptoms and the importance of treatment. As individuals become more informed, they are more likely to seek antihistamine medications for relief. This heightened awareness is expected to contribute to the market's growth trajectory, with estimates suggesting a market value of 0.17 USD Billion in 2024. The proactive approach to allergy management may further enhance the demand for antihistamines.

    Increased Self-Medication Trends

    The trend towards self-medication is becoming increasingly prevalent, particularly in the context of antihistamine drugs. Consumers are more inclined to purchase over-the-counter antihistamines for managing mild allergy symptoms without consulting healthcare professionals. This shift is evident in the Global Antihistamine Drugs Market Industry, where the convenience of access to these medications is driving sales. The market is expected to grow at a compound annual growth rate of 8.93 percent from 2025 to 2035, reflecting the rising consumer confidence in self-treatment options. This trend may lead to a more significant share of the market being attributed to non-prescription antihistamines.

    Advancements in Drug Formulations

    Innovations in drug formulations are significantly influencing the Global Antihistamine Drugs Market Industry. The development of newer antihistamines with improved efficacy and fewer side effects enhances patient compliance and satisfaction. For example, the introduction of long-acting formulations allows for once-daily dosing, which is particularly appealing to patients. These advancements are likely to contribute to the market's expansion, with a projected growth to 0.44 USD Billion by 2035. The continuous evolution of drug delivery systems and formulations may also attract new consumer segments, thereby broadening the market base.

    Regulatory Support for Antihistamines

    Regulatory bodies are increasingly supporting the development and approval of antihistamine drugs, which is beneficial for the Global Antihistamine Drugs Market Industry. Streamlined approval processes and guidelines for new antihistamine formulations encourage pharmaceutical companies to invest in research and development. This regulatory environment fosters innovation and the introduction of new products into the market. As a result, the market is projected to grow significantly, reaching 0.44 USD Billion by 2035. The supportive regulatory framework may also enhance competition among manufacturers, leading to a wider variety of antihistamine options for consumers.

    Market Segment Insights

    Antihistamine Drugs Type Insights

    The Antihistamine Drugs market segmentation, based on type, includes Sedating and Non-Sedating. The non-sedating category dominated the market, accounting for 51% of market revenue (USD 0.1 billion) in 2022 due to its increased preference by patients and easy availability.

    Figure 1: Antihistamine Drugs Market, by Type, 2022 & 2032 (USD Billion) 

    Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

    Antihistamine Drugs Route of Administration Insights

    The Antihistamine Drugs market segmentation, based on the route of administration, includes oral route, parenteral route, and rectal route. The oral route category generated the highest revenue of about 45% (USD 0.07 billion) in 2022 due to its increased benefits and ease of availability.

    Antihistamine Drugs Indication Insights

    The Antihistamine Drugs market segmentation, based on Indication, includes Allergy, Urticaria, and Dermatitis. The allergy category dominated the market, accounting for 39% of the market share (USD 0.06 billion) in 2022. Category growth is driven by the growing elderly population and the advent of innovative medication regimens used to manage allergic diseases that will accelerate market expansion.

    Antihistamine Drugs End User Insights

    The Antihistamine Drugs market segmentation, based on End Users, includes Hospitals, Clinics, and Pharmaceutical Companies. Hospitals dominated the market, accounting for 46% of market revenue (USD 0.07 billion) in 2022. Hospitals are in charge of giving medications that either cure or assist patients in maintaining their illnesses. As a result of their success in managing allergies affecting the nose and eyes, they have gained competence in prescribing antihistamines.

    News

    A recent study has discovered concrete proof that an over-the-counter antihistamine may repair the multiple sclerosis patient's destroyed protective nerve sheath. The discovery of a biomarker by researchers, which can be used to gauge a drug's efficacy, has led to the possibility of a brand-new treatment for the crippling condition. The protective myelin coating surrounding nerves is attacked by the body's immune system in the autoimmune condition multiple sclerosis (MS), resulting in irreparable damage and obstructing brain-body communication. The symptoms of demyelination, or the breakdown of myelin, can range in intensity from tingling and numbness to vision impairment and paralysis.

    Get more detailed insights about Antihistamine Drugs Market Research Report - Forecast Till 2032

    Regional Insights

    By region, the research provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Antihistamine Drugs market will dominate this market, owing to the increased incidence of allergic rhinitis and the increasing need for evaluating and managing allergic illnesses.

    Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 2: Antihistamine Drugs Market Share by Region 2022 (USD Billion) 

    Antihistamine Drugs Market Share by Region 2022

    Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

    Europe region’s Antihistamine Drugs market accounts for the second-highest market share. Per the European Academy of Allergies and Clinical Immunology (EAACI), allergies will impact over fifty percent of all Europeans in the next years, boosting the overall market. Further, the German Antihistamine Drugs market holds the largest market share, and the UK Antihistamine Drugs market is anticipated to grow and expand steadily in the European region during the projected timeframe.

    The Asia-Pacific Antihistamine Drugs Market is expected to grow significantly during the projected timeframe. This is due to increased demand for pharmaceuticals for treating allergies and skin problems. Moreover, China’s Antihistamine Drugs market dominates the market share, and the Indian Antihistamine Drugs market is anticipated to grow rapidly in the Asia-Pacific region during the projected timeframe.

    Key Players and Competitive Insights

    Leading market players invested heavily in research and development (R&D) to scale up their manufacturing units and product lines, which will help the Antihistamine Drugs market grow worldwide. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their footprint, with important market developments including new product portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings.

    The Antihistamine Drugs industry must offer cost-effective and sustainable options to survive in a dynamic market.

    Manufacturing locally to minimize operational expenses and offer aftermarket services to customers is one of the key business strategies organizations use in the Antihistamine Drugs industry to benefit customers and capture untapped market share and revenue. The Antihistamine Drugs industry has recently offered significant advantages to the medicine and service industry. Moreover, more industry participants are utilizing and adopting cutting-edge technology has grown substantially.

    Major players in the Antihistamine Drugs market, including Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.), are attempting to expand market share and demand by investing in research and development (R&D) operations to produce sustainable and affordable solutions.

    Bayer AG is a German international pharma and biotech corporation, one of the world's leading pharma corporations. It was created in 1863 by chemical merchant Friedrich Bayer and dye firm owner Johann Friedrich Wescott. The company’s headquarters are in Leverkusen, Germany. It develops, manufactures, and distributes goods in medical treatment, dietary habits, and technologically advanced materials. Pharmaceuticals, Crop Science, Consumer Health, Animal Health, and Covestro are its business segments. The Pharmaceuticals division develops, manufactures, and markets prescription drugs for cardiac and women's medical care; specialty therapies in cancer, hematology, and ophthalmology; and medical imaging devices and contrast agents.

    The FDA authorized Bayer AG's Astepro to treat periodic and chronic allergies for non-prescription usage beginning in June 2021 via a temporary to non-prescription transfer. This FDA clearance has given people access to a secure, efficient nostril antihistamine without needing a healthcare practitioner.

    Glenmark Pharma is a prominent creative pharmaceutical firm dedicated to improving people's lives worldwide. Gracias Saldanha created it in 1977, and it has its headquarters in Mumbai, India. They aim to uncover novel opportunities and improve the well-being of patients worldwide by creating remedies for medical gaps. They have a robust pipeline of new compounds in various stages of discovery aimed at lung disease, cancer, and skincare. Glenmark Pharma is developing cutting-edge treatments for an emerging world. Glenmark has almost 6000 employees spread throughout 80 countries, including 12 production facilities.

    Glenmark Pharma will introduce Ryaltris, a novel spray for the nose, in India in May 2021. Glenmark is an innovator in the pulmonary area, having been the first to launch labeled versions cheaply in India.

    Key Companies in the Antihistamine Drugs Market market include

    Industry Developments

    • Q2 2024: FDA Approves First Generic Version of Xyzal (levocetirizine dihydrochloride) Oral Solution The FDA approved the first generic version of Xyzal (levocetirizine dihydrochloride) oral solution for the treatment of indoor and outdoor allergies, expanding access to a widely used second-generation antihistamine.
    • Q1 2024: Sanofi launches Allegra-D 24 Hour Allergy & Congestion in new extended-release formulation in the U.S. Sanofi announced the launch of a new extended-release formulation of Allegra-D 24 Hour, providing all-day relief for allergy and nasal congestion symptoms, further strengthening its OTC antihistamine portfolio.
    • Q2 2024: GSK receives European Commission approval for over-the-counter sale of Clarinex (desloratadine) in select EU countries GSK announced that the European Commission has approved the switch of Clarinex (desloratadine) from prescription to over-the-counter status in several European Union countries, increasing consumer access to the antihistamine.
    • Q3 2024: Pfizer completes acquisition of allergy drugmaker Allermi for $1.2 billion Pfizer finalized its acquisition of Allermi, a specialty pharmaceutical company focused on innovative antihistamine nasal sprays, expanding Pfizer’s allergy treatment portfolio.
    • Q2 2024: Bayer opens new manufacturing facility for Claritin production in Germany Bayer inaugurated a new state-of-the-art manufacturing facility in Leverkusen, Germany, dedicated to increasing production capacity for its leading antihistamine brand, Claritin.
    • Q1 2025: Novartis announces partnership with Alnylam to develop next-generation antihistamine therapies Novartis and Alnylam Pharmaceuticals entered a strategic partnership to co-develop RNAi-based antihistamine drugs targeting severe allergic conditions, aiming to advance novel treatment options.
    • Q2 2025: Johnson & Johnson acquires rights to new pediatric antihistamine syrup from BioPharmX Johnson & Johnson acquired exclusive global rights to a novel pediatric antihistamine syrup developed by BioPharmX, expanding its children’s allergy medication offerings.
    • Q1 2024: Takeda receives Japanese regulatory approval for Telfast ODT (orally disintegrating tablet) for allergic rhinitis Takeda announced that Japan’s Ministry of Health, Labour and Welfare approved Telfast ODT, an orally disintegrating tablet formulation of the antihistamine fexofenadine, for the treatment of allergic rhinitis.
    • Q3 2024: AstraZeneca launches new combination antihistamine and corticosteroid nasal spray in the UK AstraZeneca introduced a new prescription nasal spray combining an antihistamine and corticosteroid for the treatment of moderate to severe allergic rhinitis in the United Kingdom.
    • Q2 2025: Arcutis Biotherapeutics raises $150 million in IPO to advance topical antihistamine pipeline Arcutis Biotherapeutics completed its initial public offering, raising $150 million to fund the development and commercialization of its pipeline of topical antihistamine therapies for dermatological allergies.
    • Q1 2025: Merck & Co. announces global supply agreement with Walgreens for OTC antihistamine Zyrtec Merck & Co. entered into a multi-year global supply agreement with Walgreens to distribute its over-the-counter antihistamine Zyrtec across Walgreens’ international retail network.
    • Q2 2024: UCB receives FDA approval for expanded use of Xyzal in children aged 2-5 years UCB announced that the FDA approved the expanded use of Xyzal (levocetirizine dihydrochloride) for the treatment of allergic rhinitis in children aged 2 to 5 years, broadening the drug’s pediatric indications.

    Future Outlook

    Antihistamine Drugs Market Future Outlook

    The Antihistamine Drugs Market is projected to grow at 8.93% CAGR from 2024 to 2035, driven by rising allergy prevalence, innovative drug formulations, and increasing consumer awareness.

    New opportunities lie in:

    • Develop targeted antihistamine therapies for specific demographics, enhancing efficacy and patient satisfaction.
    • Invest in digital health platforms for personalized allergy management solutions, leveraging data analytics.
    • Expand distribution channels in emerging markets to capture untapped consumer segments and increase market share.

    By 2035, the Antihistamine Drugs Market is expected to achieve substantial growth, reflecting evolving consumer needs and innovative product developments.

    Market Segmentation

    Antihistamine Drugs Type Outlook

    • Sedating
    • Non-Sedating

    Antihistamine Drugs End User Outlook

    • Hospitals
    • Clinics
    • Pharmaceutical Companies

    Antihistamine Drugs Regional Outlook

    • US
    • Canada

    Antihistamine Drugs Indication Outlook

    • Allergy
    • Urticaria
    • Dermatitis

    Antihistamine Drugs Route of Administration Outlook

    • Oral Route
    • Parenteral Route
    • Rectal Route

    Report Scope

    Attribute/Metric Details
    Market Size 2023 USD 0.16 Billion
    Market Size 2024 USD 0.17 Billion
    Market Size 2032 USD 0.34 Billion
    Compound Annual Growth Rate (CAGR) 8.60% (2024-2032)
    Base Year 2022
    Market Forecast Period 2024-2032
    Historical Data 2018- 2022
    Market Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Type, Route of Administration, Indication, End-User, and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled  Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.)
    Key Market Opportunities Product releases and research and development by significant critical market participants
    Key Market Dynamics Allergic rhinitis is frequent. Raising awareness about  therapies related to allergy

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    How much is the Antihistamine Drugs market?

    The Antihistamine Drugs market size was valued at USD 0.16 Billion in 2023.

    What is the growth rate of the Antihistamine Drugs market?

    The market is projected to grow at a CAGR of 8.60% during the forecast period, 2024-2032.

    Which region held the largest market share in the Antihistamine Drugs market?

    North America holds the largest share of the Antihistamine Drugs market.

    Who are the key players in the Antihistamine Drugs market?

    The key players in the market are Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.).

    Which type led the Antihistamine Drugs market?

    Non-Sedating dominated the market in 2023.

    Which Route of Administration had the largest market share in the Antihistamine Drugs market?

    The Oral Route had the largest share of the market.

    1. Brief TOC    
    2.     Report Prologue  
    3.     Market Introduction    
      1.     Definition    
      2.     Scope of the Study    
        1.     Research Objective  
        2.     Assumptions    
    4.  Limitations    
    5.     Research Methodology
      1.     Introduction
      2.     Primary Research  
      3.     Secondary research    
    6.  Market Size Estimation
    7.     Market Dynamics
      1.     Drivers    
      2.     Restrains
      3.     Opportunities    
      4.     Challenges
      5.     Macroeconomic Indicators
      6.     Technology
    8. Trends & Assessment            
    9.     Market Factor Analysis
    10.  Porters five Forces Analysis
      1.     Bargaining Power
    11. of Suppliers    
      1.     Bargaining Power of
    12. Buyers
      1.     Threat of New Entrants    
        1.     Threat of Substitutes    
    13.  Intensity of Rivalry    
      1.     Value Chain
      2.     Investment Feasibility Analysis    
    14.  Price Factor Analysis
    15.     Global Antihistamine
    16. drugs Market, by Type
      1.     Introduction  
      2.     Sedating Antihistamine Drugs
    17.  Brompheniramine
      1.     Chlorpheniramine 
    18.  Diphenhydramine 
      1.     Doxylamine 
    19.  Carbinoxamine
      1.     Others    
    20.  Non-Sedating Antihistamine Drugs
    21.  Fexofenadine 
      1.     Loratadine 
    22.  Loratadine ODT
      1.     Others
    23.  Global Antihistamine Drugs Market, By Route of Administration
      1.     Introduction    
      2.     Oral
    24. Route
      1.     Parenteral Route 
        1.     Intramuscular
        2.     Subcutaneous 
        3.     Intravenous
    25. Route
      1.     Rectal Route
    26.     Global
    27. Antihistamine Drugs Market, by Indication
      1.     Introduction
      2.     Allergy 
      3.     Urticaria 
      4.     Dermatitis 
      5.     Others
    28.  Global Antihistamine Drugs Market by End User
    29.  Introduction
    30.     9.2    Hospitals
    31.  Clinics
      1.     Pharmaceutical Companies
    32.  Others    
    33.     Global Antihistamine
    34. Drugs Market by Region
      1.     Introduction
    35.  Americas    
      1.     North America  
        1.     U.S.    
    36.  Canada    
      1.     Latin America  
      2.     Europe    
    37.  Western Europe    
      1.     Germany  
        1.     France    
    38.  UK    
      1.     Italy    
        1.     Spain    
    39.  Rest of Western Europe    
      1.     Eastern
    40. Europe    
      1.     Asia Pacific
    41.  Japan    
      1.     China    
        1.     India    
        2.     Republic
    42. of Korea    
      1.     Australia  
        1.     Rest of Asia Pacific    
      2.     Middle East & Africa    
    43.  United Arab Emirates    
      1.     Saudi
    44. Arabia    
      1.     Oman    
        1.     Kuwait    
        2.     Qatar  
        3.     Rest of Middle East & Africa  
    45.     Company Landscape    
      1.     Introduction    
      2.     Market
    46. Share Analysis    
      1.     Key Development &
    47. Strategies    
      1.     Key Developments  
    48.     Company Profiles    
      1.     Johnson & Johnson Consumer Inc.
    49.  Company Overview    
      1.     Product
    50. Overview    
      1.     Financials  
        1.     SWOT Analysis    
    51.  Sanofi
      1.     Company Overview    
        1.     Product Overview    
    52.  Financial Overview    
      1.     Key Developments  
        1.     SWOT Analysis    
    53.  Bayer AG
      1.     Company Overview    
        1.     Product Overview    
    54.  Financial Overview
      1.     Key Development  
        1.     SWOT Analysis    
    55.  Pfizer
      1.     Company Overview    
        1.     Product/Business Segment Overview    
        2.     Financial Overview    
    56.  Key Development    
      1.     SWOT Analysis  
      2.     Merck Sharp & Dohme Corp.
    57.  Company Overview    
      1.     Product
    58. Overview    
      1.     Financial Overview  
        1.     Key Developments    
    59.  Prestige Brands Holdings, Inc.
      1.     Company Overview  
        1.     Product Overview    
    60.  Financial Overview    
      1.     Key Developments  
      2.     CVS Pharmacy
        1.     Overview  
        2.     Product Overview    
    61.  Financials    
      1.     Key Developments  
        1.     SWOT Analysis    
    62.  MRFR Conclusion    
      1.     Key Findings    
        1.     From CEO’s View
    63. Point    
      1.     Unmet Needs of the Market  
      2.     Key Companies to Watch    
      3.     Prediction of Pharmaceutical Industry
    64.  Appendix

    Market Segmentation

    Antihistamine Drugs Type Outlook (USD Billion, 2018-2032)

    • Sedating
    • Non-Sedating

    Antihistamine Drugs Route of Administration Outlook (USD Billion, 2018-2032)

    • Oral Route
    • Parenteral Route
    • Rectal Route

    Antihistamine Drugs Indication Outlook (USD Billion, 2018-2032)

    • Allergy
    • Urticaria
    • Dermatitis

    Antihistamine Drugs End User Outlook (USD Billion, 2018-2032)

    • Hospitals
    • Clinics
    • Pharmaceutical Companies

    Antihistamine Drugs Regional Outlook (USD Billion, 2018-2032)

    • North America Outlook (USD Billion, 2018-2032)

      • North America Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • North America Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • North America Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • North America Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • US Outlook (USD Billion, 2018-2032)

      • US Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • US Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • US Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • US Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • Canada Outlook (USD Billion, 2018-2032)

      • Canada Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Canada Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Canada Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • Canada Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
    • Europe Outlook (USD Billion, 2018-2032)

      • Europe Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Europe Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Europe Antihistamine Drugs by Indication

        • Allergy
        • Urticaria
        • Dermatitis
      • Europe Antihistamine Drugs by End User

        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • Germany Outlook (USD Billion, 2018-2032)

      • Germany Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Germany Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Germany Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • Germany Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • France Outlook (USD Billion, 2018-2032)

      • France Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • France Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • France Antihistamine Drugs by Indication

        • Allergy
        • Urticaria
        • Dermatitis
      • France Antihistamine Drugs by End User

        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • UK Outlook (USD Billion, 2018-2032)

      • UK Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • UK Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • UK Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • UK Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • Italy Outlook (USD Billion, 2018-2032)

      • Italy Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Italy Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Italy Antihistamine Drugs by Indication

        • Allergy
        • Urticaria
        • Dermatitis
      • Italy Antihistamine Drugs by End User

        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • Spain Outlook (USD Billion, 2018-2032)

      • Spain Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Spain Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Spain Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • Spain Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • Rest Of Europe Outlook (USD Billion, 2018-2032)

      • Rest Of Europe Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Rest Of Europe Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Rest Of Europe Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • Rest Of Europe Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
    • Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Asia-Pacific Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Asia-Pacific Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Asia-Pacific Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • Asia-Pacific Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • China Outlook (USD Billion, 2018-2032)

      • China Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • China Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • China Antihistamine Drugs by Indication

        • Allergy
        • Urticaria
        • Dermatitis
      • China Antihistamine Drugs by End User

        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • Japan Outlook (USD Billion, 2018-2032)

      • Japan Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Japan Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Japan Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • Japan Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • India Outlook (USD Billion, 2018-2032)

      • India Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • India Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • India Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • India Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • Australia Outlook (USD Billion, 2018-2032)

      • Australia Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Australia Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Australia Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • Australia Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Rest of Asia-Pacific Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Rest of Asia-Pacific Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Rest of Asia-Pacific Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • Rest of Asia-Pacific Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
    • Rest of the World Outlook (USD Billion, 2018-2032)

      • Rest of the World Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Rest of the World Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Rest of the World Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • Rest of the World Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • Middle East Outlook (USD Billion, 2018-2032)

      • Middle East Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Middle East Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Middle East Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • Middle East Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • Africa Outlook (USD Billion, 2018-2032)

      • Africa Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Africa Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Africa Antihistamine Drugs by Indication

        • Allergy
        • Urticaria
        • Dermatitis
      • Africa Antihistamine Drugs by End User

        • Hospitals
        • Clinics
        • Pharmaceutical Companies
      • Latin America Outlook (USD Billion, 2018-2032)

      • Latin America Antihistamine Drugs by Type
        • Sedating
        • Non-Sedating
      • Latin America Antihistamine Drugs by Route of Administration
        • Oral Route
        • Parenteral Route
        • Rectal Route
      • Latin America Antihistamine Drugs by Indication
        • Allergy
        • Urticaria
        • Dermatitis
      • Latin America Antihistamine Drugs by End User
        • Hospitals
        • Clinics
        • Pharmaceutical Companies
    Antihistamine Drugs Market Research Report - Forecast Till 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials